PX2 Technology – PathogenX Announces National Distribution

Carmel-based PathogenX, a medical device company which develops, manufactures, and distributes proprietary technology designed to dramatically simplify the process of medical waste disposal, today announced that full national distribution throughout the United States and Canada is now available for its unique, double-batch, on-site sterilization device, the PX2.

PathogenX’s PX2 is a stand-alone device (about the size of a laser printer) that safely and efficiently renders regulated medical waste (such as sharps) completely sterile, unrecognizable and non-reusable in compliance with all federal EPA, CDC and OSHA standards and guidelines. Each PX2 device is capable of processing up to 10 gallons of medical waste per day.

The PX2 system destroys all microbes, including COVID-19, while melting the biomedical waste so that a resulting “brick” of harmless, sterilized material can be easily disposed of in the standard trash.

The technology is now available throughout the United States and Canada for use by hospitals and health facilities; research centers and laboratories; mortuary and autopsy centers; animal research and testing laboratories; veterinary facilities; blood banks; nursing homes for the elderly; and other health-related venues where blood is drawn.

“It’s rewarding to be able to now provide our PX2 technology on a national level,” said PathogenX CEO Chuck Berkeley. “This technology is ultra-safe and easy-to-use and we see it as a genuine game-changer for doctors, dentists, vets, sports teams, home health care workers, nursing homes, and any other organizations that have been dealing with the expensive and dangerous nuisance of generating modest amounts of medical waste. Especially today, with the ongoing battle against COVID-19, we are proud to provide something to healthcare workers on the front lines that removes the risk-related issues of having to manage contaminated sharps.”

Disposing of medical waste on-site with the PX2 is also considerably less expensive than haul-and-treat services and the company offers its customers financing and lease-to-own options so that the device pays for itself.

SourcePathogenX

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”